Neurosyphilis and HIV Infection

Chapter
First Online:

Abstract

Syphilis and HIV are both diseases of major public health importance globally, affecting tens of millions of people and leading to millions of deaths every year. There is a complex demographic, epidemiologic, and biologic interaction between the HIV virus and Treponema pallidum, the causative agent of syphilis. These interactions lead not only to higher rates of coinfection but also are believed to affect pathogenic mechanisms that result in early central nervous system syphilis among HIV-coinfected patients. Acute syphilitic meningitis and neuro-ophthalmologic syphilitic involvement are also believed to occur at a higher rate and early in the course of syphilis among HIV-coinfected individuals. There needs to be a higher index of suspicion for syphilitic involvement of the CNS among HIV patients especially those with ophthalmological and/or ontological complaints. While there may need to be subtle differences, current recommendations for diagnostic workup for neurosyphilis in HIV-coinfected patients are similar to that of non-HIV patients. Intravenous penicillin remains the treatment of choice for neurosyphilis.

Keywords

Syphilis-HIV Treponema pallidum Neurosyphilis Ocular syphilis Otosyphilis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    World Health Organization (2012) Global incidence and prevalence of selected curable sexually transmitted infections-2008. World Health OrganizationGoogle Scholar
  2. 2.
    Dickerson MC, Johnston J, Delea TE et al (1996) The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus: an application of the Bradford hill criteria. Sex Transm Dis 23:429–440CrossRefPubMedGoogle Scholar
  3. 3.
    Nnoruka EN, Ezeoke A (2005) Evaluation of syphilis in patients with HIV infection in Nigeria. Tropical Med Int Health 10:58–64CrossRefGoogle Scholar
  4. 4.
    Shimelis T, Lemma K, Ambachew H et al (2015) Syphilis among people with HIV infection in southern ethiopia: sero-prevalence and risk factors. BMC Infect Dis 15:1CrossRefGoogle Scholar
  5. 5.
    Firlag-Burkacka E, Cielniak I, Swiecki P et al (2013) The increasing prevalence of neurosyphilis and high serum VDRL titers in HIV positive patients—Data from outpatient clinic in Warsaw, Poland (POLCA cohort). HIV & AIDS Rev 12:34–36CrossRefGoogle Scholar
  6. 6.
    Tucker JD, Chen X, Peeling RW (2010) Syphilis and social upheaval in China. N Engl J Med 362:1658–1661CrossRefPubMedGoogle Scholar
  7. 7.
    Piot P, Bartos M, Ghys PD et al (2001) The global impact of HIV/AIDS. Nature 410:968–973CrossRefPubMedGoogle Scholar
  8. 8.
    Ortblad KF, Lozano R, Murray CJ (2013) The burden of HIV: insights from the global burden of disease study 2010. AIDS 27:2003–2017CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chesson HW, Heffelfinger JD, Voigt RF et al (2005) Estimates of primary and secondary syphilis rates in persons with HIV in the united states, 2002. Sex Transm Dis 32:265–269CrossRefPubMedGoogle Scholar
  10. 10.
    Blocker ME, Levine WC, Louis MES (2000) HIV prevalence in patients with syphilis, United States. Sex Transm Dis 27:53–59CrossRefPubMedGoogle Scholar
  11. 11.
    Hutchinson CM, Hook EW, Shepherd M et al (1994) Altered clinical presentation of early syphilis in patients with human immunodeficiency virus infection. Ann Intern Med 121:9CrossRefGoogle Scholar
  12. 12.
    Wu L, Paxton WA, Kassam N et al (1997) CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 185:1681–1692CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sellati TJ, Wilkinson DA, Sheffield JS et al (2000) Virulent Treponema pallidum, lipoprotein, and synthetic lipopeptides induce CCR5 on human monocytes and enhance their susceptibility to infection by human immunodeficiency virus type 1. J Infect Dis 181:283–293CrossRefPubMedGoogle Scholar
  14. 14.
    Johns DR, Tierney M, Felsenstein D (1987) Alteration in the natural history of neurosyphilis by concurrent infection with the human immunodeficiency virus. N Engl J Med 316:1569–1572CrossRefPubMedGoogle Scholar
  15. 15.
    Collart P, Franceschini P, Durel P (1971) Experimental rabbit syphilis. Br J Vener Dis 47:389PubMedPubMedCentralGoogle Scholar
  16. 16.
    Lukehart SA, Hook EW, Baker-Zander SA et al (1988) Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 109:855–862CrossRefPubMedGoogle Scholar
  17. 17.
    Chesney AM, Kemp JE (1924) Incidence of spirochaeta pallida in cerebrospinal fluid during early stage of syphilis. J Am Med Assoc 83:1725–1728CrossRefGoogle Scholar
  18. 18.
    Chung KY, Lee MG, Lee JB (1994) Detection of Treponema pallidum by polymerase chain reaction in the cerebrospinal fluid of syphilis patients. Yonsei Med J 35:190CrossRefPubMedGoogle Scholar
  19. 19.
    Ghanem KG (2010) REVIEW: Neurosyphilis: a historical perspective and review. CNS Neurosci Ther 16:e168CrossRefGoogle Scholar
  20. 20.
    Keidel A (1922) Studies in asymptomatic neurosyphilis: IV. The apparent role of immunity in the genesis of neurosyphilis. J Am Med Assoc 79:874–876CrossRefGoogle Scholar
  21. 21.
    Amaratunge BC, Camuglia JE, Hall AJ (2010) Syphilitic uveitis: a review of clinical manifestations and treatment outcomes of syphilitic uveitis in human immunodeficiency virus-positive and negative patients. Clin Experiment Ophthalmol 38:68–74CrossRefPubMedGoogle Scholar
  22. 22.
    Flood JM, Weinstock HS, Guroy ME et al (1998) Neurosyphilis during the AIDS epidemic, San Francisco, 1985–1992. J Infect Dis 177:931–940CrossRefPubMedGoogle Scholar
  23. 23.
    Ghanem KG, Moore RD, Rompalo AM et al (2008) Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 22:1145CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rolfs RT (1995) Treatment of syphilis, 1993. Clin Infect Dis 20:S38CrossRefGoogle Scholar
  25. 25.
    Rolfs RT, Joesoef MR, Hendershot EF et al (1997) A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med 337:307–314CrossRefPubMedGoogle Scholar
  26. 26.
    Feraru ER, Aronow HA, Lipton RB (1990) Neurosyphilis in AIDS patients Initial CSF VDRL may be negative. Neurology 40(3 Part 1):541–541CrossRefPubMedGoogle Scholar
  27. 27.
    Blanco DR, Miller JN, Lovett MA (1997) Surface antigens of the syphilis spirochete and their potential as virulence determinants. Emerg Infect Dis 3:11CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Fraser CM, Norris SJ, Weinstock GM et al (1998) Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 281:375–388CrossRefPubMedGoogle Scholar
  29. 29.
    Cox DL, Chang P, McDowall AW et al (1992) The outer membrane, not a coat of host proteins, limits antigenicity of virulent Treponema pallidum. Infect Immun 60:1076–1083PubMedPubMedCentralGoogle Scholar
  30. 30.
    Chamberlain NR, Brandt ME, Erwin AL et al (1989) Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect Immun 57:2872–2877PubMedPubMedCentralGoogle Scholar
  31. 31.
    Murphy PM (2001) Viral exploitation and subversion of the immune system through chemokine mimicry. Nat Immunol 2:116–122CrossRefPubMedGoogle Scholar
  32. 32.
    Ke W, Molini BJ, Lukehart SA et al (2015) Treponema pallidum subsp. pallidum TP0136 protein is heterogeneous among isolates and binds cellular and plasma fibronectin via its NH 2-terminal end. PLoS Negl Trop Dis 9:e0003662CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Baseman JB, Alderete JF (1983) The parasitic strategies of Treponema pallidum. In: Schell D, Museher R (eds) Immunology of Treponema infections, vol 20. Marcel Dekker, Inc., New York, p 229Google Scholar
  34. 34.
    Cameron CE (2003) Identification of a Treponema pallidum laminin-binding protein. Infect Immun 71:2525–2533CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Riley BS, Oppenheimer-Marks N, Hansen EJ et al (1992) Virulent Treponema pallidum activates human vascular endothelial cells. J Infect Dis 165:484–493CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang R, Wang Q, Zhang J et al (2015) Tp17 membrane protein of Treponema pallidum activates endothelial cells in vitro. Int Immunopharmacol 25:538–544CrossRefPubMedGoogle Scholar
  37. 37.
    Centers for Disease Control and Prevention (CDC) (2007) Symptomatic early neurosyphilis among HIV-positive men who have sex with men – four cities, United States, January 2002-June 2004. MMWR Morb Mortal Wkly Rep 56:625Google Scholar
  38. 38.
    Adams RD, Merritt HH (1944) Meningeal and vascular syphilis of the spinal cord. Medicine 23:181–214CrossRefGoogle Scholar
  39. 39.
    Clark EG, Danbolt N (1955) The oslo study of the natural history of untreated syphilis: an epidemiologic investigation based on a restudy of the Boeck-Bruusgaard material a review and appraisal. J Chronic Dis 2:311–344CrossRefPubMedGoogle Scholar
  40. 40.
    Bayne LL, Schmidley JW, Goodin DS (1986) Acute syphilitic meningitis: its occurrence after clinical and serologic cure of secondary syphilis with penicillin G. Arch Neurol 43:137–138CrossRefPubMedGoogle Scholar
  41. 41.
    Weinert LS, Scheffel RS, Zoratto G et al (2008) Cerebral syphilitic gumma in HIV-infected patients: case report and review. Int J STD AIDS 19:62–64CrossRefPubMedGoogle Scholar
  42. 42.
    Philip SS, Klausner JD. Neurosyphilis in HIV-infected patients. 2008.Google Scholar
  43. 43.
    Mishra S, Walmsley SL, Loutfy MR et al (2008) Otosyphilis in HIV-coinfected individuals: a case series from Toronto, Canada. AIDS Patient Care STDs 22:213–219CrossRefPubMedGoogle Scholar
  44. 44.
    Poliseli R, Vidal JE, De O, Penalva AC et al (2008) Neurosyphilis in HIV-infected patients: clinical manifestations, serum venereal disease research laboratory titers, and associated factors to symptomatic neurosyphilis. Sex Transm Dis 35:425–429CrossRefPubMedGoogle Scholar
  45. 45.
    Balba GP, Kumar PN, James AN et al (2006) Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy. Am J Med 119:448.E25CrossRefGoogle Scholar
  46. 46.
    Marra CM (2004) Neurosyphilis. Curr Neurol Neurosci Rep 4:435–440CrossRefPubMedGoogle Scholar
  47. 47.
    Kiss S, Damico FM, Young LH (2005) Ocular manifestations and treatment of syphilis. Seminars in ophthalmology. Taylor & Francis, pp 161–167. Published online 2 Jul, 2009Google Scholar
  48. 48.
    Tucker JD, Li JZ, Robbins GK et al (2011) Ocular syphilis among HIV-infected patients: a systematic analysis of the literature. Sex Transm Infect 87:4–8CrossRefPubMedGoogle Scholar
  49. 49.
    Gaudio PA (2006) Update on ocular syphilis. Curr Opin Ophthalmol 17:562–566CrossRefPubMedGoogle Scholar
  50. 50.
    Shalaby IA, Dunn JP, Semba RD et al (1997) Syphilitic uveitis in human immunodeficiency virus—infected patients. Arch Ophthalmol 115:469–473CrossRefPubMedGoogle Scholar
  51. 51.
    Hooshmand H, Escobar MR, Kopf SW (1972) Neurosyphilis: a study of 241 patients. JAMA 219:726–729CrossRefPubMedGoogle Scholar
  52. 52.
    Holmes MD, Brant-Zawadzki MM, Simon RP (1984) Clinical features of meningovascular syphilis. Neurology 34:553CrossRefPubMedGoogle Scholar
  53. 53.
    Harrigan EP, McLaughlin TJ, Feldman RG (1984) Transverse myelitis due to meningovascular syphilis. Arch Neurol 41:337–338CrossRefPubMedGoogle Scholar
  54. 54.
    Luo W, Ouyang Z, Xu H et al (2008) The clinical analysis of general paresis with 5 cases. J Neuropsychiatry Clin Neurosci 20:490–493CrossRefPubMedGoogle Scholar
  55. 55.
    Hattori T, Yasuda K, Kita K et al (1990) Disorders of micturition in tabes dorsalis. Br J Urol 65:497–499CrossRefPubMedGoogle Scholar
  56. 56.
    Osman C, Clark T, Ghosh B et al (2015) Tabes dorsalis in the post antibiotic era: never say never. J Neurol Neurosurg Psychiatry e4:86Google Scholar
  57. 57.
    Musher DM, Baughn RE (1994) Neurosyphilis in HIV-infected persons. N Engl J Med 331:1516–1517CrossRefPubMedGoogle Scholar
  58. 58.
    Kingston AA, Vujevich J, Shapiro M et al (2005) Seronegative secondary syphilis in 2 patients coinfected with human immunodeficiency virus. Arch Dermatol 141:431–433CrossRefPubMedGoogle Scholar
  59. 59.
    Workowski KA, Bolan GA (2015) Sexually transmitted diseases treatment guidelines. Reprod Endocrinol 24:51–56Google Scholar
  60. 60.
    Ghanem KG, Moore RD, Rompalo AM et al (2009) Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 48:816–821CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Yang C, Chang S, Hung C (2009) Sensitivity and specificity of lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 49:162CrossRefPubMedGoogle Scholar
  62. 62.
    Ratnam S (2005) The laboratory diagnosis of syphilis. Can J Infect Dis Med Microbiol 16:45–51PubMedPubMedCentralGoogle Scholar
  63. 63.
    Larsen SA, Pope V, Johnson RE et al (2008) A manual of tests for syphilis. Washington, DC: American Public Health Association, 1998. Anaesth Intensive Care 36:260–272Google Scholar
  64. 64.
    Smith G, Holman RP (2004) The prozone phenomenon with syphilis and HIV-1 co-infection. South Med J 97:379–383CrossRefPubMedGoogle Scholar
  65. 65.
    Hagedorn H, Kraminer-Hagedorn A, De Bosschere K et al (2002) Evaluation of INNO-LIA syphilis assay as a confirmatory test for syphilis. J Clin Microbiol 40:973–978CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Wicher K, Horowitz HW, Wicher V (1999) Laboratory methods of diagnosis of syphilis for the beginning of the third millennium. Microb Infect 1:1035–1049CrossRefGoogle Scholar
  67. 67.
    Castro RR, Prieto ES, Santo I et al (2001) Evaluation of the passive particle agglutination test in the serodiagnosis and follow-up of syphilis. Am J Clin Pathol 116:581–585CrossRefPubMedGoogle Scholar
  68. 68.
    Gutirrez J, Vergara MJ, Soto MJ et al (2000) Clinical utility of a competitive ELISA to detect antibodies against Treponema pallidum. J Clin Lab Anal 14:83–86CrossRefGoogle Scholar
  69. 69.
    Byrne RE, Laska S, Bell M et al (1992) Evaluation of a Treponema pallidum western immunoblot assay as a confirmatory test for syphilis. J Clin Microbiol 30:115–122PubMedPubMedCentralGoogle Scholar
  70. 70.
    Sambri V, Marangoni A, Eyer C et al (2001) Western immunoblotting with five Treponema pallidum recombinant antigens for serologic diagnosis of syphilis. Clin Diagn Lab Immunol 8:534–539PubMedPubMedCentralGoogle Scholar
  71. 71.
    Herring AJ, Ballard RC, Pope V et al (2006) A multi-centre evaluation of nine rapid, point-of-care syphilis tests using archived sera. Sex Transm Infect v12:82Google Scholar
  72. 72.
    Peeling RW, Holmes KK, Mabey D et al (2006) Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect v6:82Google Scholar
  73. 73.
    Libois A, De Wit S, Poll B et al (2007) HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 34:141–144CrossRefPubMedGoogle Scholar
  74. 74.
    Chan DJ (2005) Syphilis and HIV co-infection: when is lumbar puncture indicated? Curr HIV Res 3:95–98CrossRefPubMedGoogle Scholar
  75. 75.
    Lwhagen GB (1990). Syphilis: test procedures and therapeutic strategies. Semin Dermatol. 1990 Jun; 9(2):152–9Google Scholar
  76. 76.
    Davis LE, Schmitt JW (1989) Clinical significance of cerebrospinal fluid tests for neurosyphilis. Ann Neurol 25:50–55CrossRefPubMedGoogle Scholar
  77. 77.
    Marra CM, Maxwell CL, Tantalo LC et al (2008) Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 47:893–899CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Marra CM, Maxwell CL, Smith SL et al (2004) Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 189:369–376CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.University of South Florida, Morsani College of MedicineTampaUSA

Personalised recommendations